International Council for Harmonisation (ICH) to issue revision of E6 (R2) Good Clinical Practice in the fall of 2021
The International Council for Harmonisation (ICH) is working on the revision of E6 (R2) Good Clinical Practice, the guidace addressing GCP to provide a unified standard for the ICH region and to facilitate the mutual acceptance of clinical data.
Meditrial experts are at the forefront of regulatory innovation and can help you design your trial so that you can achieve GCP principles and comply with international guidelines. Contact us today for a free consultation!
The new E6(R3) is deemed to tackle the evolving clinical trial design and use of technology in clinical research, the diversity of data sources, testing facilities, service providers, and other merging complexities of the current clinical trial environment. The update of E6 will also bring forward an advanced concept of a risk-based approach in the design and conduct of clinical trials, although E6(R2), was already focused on that aspect. Moreover, the revised E6 will take into consideration the diversity of clinical trials, as clinical trials can vary greatly and certain aspects of GCP may not be applicable to every trial.
According to ICH, “E6(R3) will be composed of an overarching principles and objectives document, Annex 1 (interventional clinical trials), and Annex 2 (additional considerations for non-traditional interventional clinical trials). The overarching principles and objectives document and Annex 1 will replace the current E6(R2).”
“The proposed revision to ICH E6 would likely primarily benefit innovators who typically conduct clinical trials, such as those in the pharmaceutical and biotech sectors. Work will also inform innovators who are utilizing or exploring the use of diverse trial types and the data sources being employed to support regulatory and healthcare related decision-making on drugs. The revised E6 will highlight that achieving GCP principles and objectives can be accomplished through the use of multiple tools and methods. It will also highlight that the implementation of GCP principles should be a thoughtful, deliberative, and risk-based process.”
Final Business Plan, ICH E6(R3): Guideline for Good Clinical Practice, Dated 17 November 2019, Endorsed by the Management Committee on 18 November 2019.
E6(R3) is expected to be released in the fall of 2021.
For more details, please see the ICH Final Business Plan on E6 revision and the Efficacy Guidelines from ICH.
Contact Meditrial for immediate assistance in Europe or the US.
Table of Contents
Getting a CE mark for medical devices: a step-by-step guide
Practical guidance on the CE mark for medical devices under EU MDR, from classification and evidence to conformity assessment and EUDAMED
A Practical RBQM Framework for Medical Device Trials
Risk-based quality management for medical device trials, with practical actions for risk assessment, monitoring, data review, and trial oversight
EU Breakthrough Medical Devices Under MDCG 2025-9 (BtX)
EU breakthrough medical devices gain a clearer regulatory pathway under MDCG 2025-9, with early advice and lifecycle evidence planning
What Swissmedic Fast-Track Means for Clinical Trial Sponsors
Swissmedic swissethics Fast-Track Pilot Project accelerates eligible trial reviews and makes coordinated regulatory preparation increasingly important.
FDA Breakthrough Device Acceleration
How innovative MedTech companies can accelerate FDA approval, secure Medicare coverage, and reach patients faster—starting with Breakthrough Device Designation.
The contribution of patient associations in clinical trials
Historically, patient organizations have had the primary purpose of supporting the communities they represented. Today, this remains a crucial function, but modes have changed, as has the role that associations and patients themselves take on [...]
This article provides general information and does not constitute regulatory or legal advice. Requirements should be confirmed for the specific study, applicable regulatory framework, and markets concerned.
